



ASX Announcement 16 December 2020

OVERSUBSCRIBED SHARE PURCHASE PLAN

Highlights

- **SPP significantly oversubscribed with applications totalling approximately A\$27.2 million**
- **To accommodate strong shareholder demand, Elixinol Global has increased the size of the SPP to approximately A\$12.3 million**
- **Funds raised from the SPP, together with the A\$8.2 million in funds raised from the Company's recent Placement, will be used to execute on the Company's strategy and pursue new growth opportunities**

Elixinol Global Limited (**Elixinol Global** or the **Company**) (**ASX:EXL**; **OTCQB:ELLXF**) is pleased to announce that its Share Purchase Plan (**SPP**), which closed on Friday, 11 December 2020, was significantly oversubscribed, with the Company receiving applications totalling approximately A\$27.2 million, well in excess of the targeted amount of A\$2 million.

Under the SPP, each Eligible Shareholder was entitled to subscribe for up to A\$30,000 of new fully paid ordinary shares (**SPP Shares**) in the Company at the Issue Price of A\$0.17 per SPP Share, subject to scale back. The SPP forms part of the capital raising as announced on 16 November 2020, which also comprised a Placement to institutional and sophisticated investors raising A\$8.2 million at A\$0.17 per share.

In recognition of the strong show of support by shareholders, the Elixinol Global Board has resolved to use its discretion to accept oversubscriptions and increase the size of the SPP to approximately A\$12.3 million for the issue of 72,313,898 SPP Shares. As a result of the strong interest in the SPP, the Company has conducted a scale back of applications in accordance with the terms and conditions set out in the [SPP Booklet](#). The scale back is on a pro rata basis having regard to the relative shareholding of eligible shareholders (as at the Record Date). In addition:

- if an applicant applied for a value of Elixinol Global shares less than their pro rata amount, then they receive the value of Elixinol Global shares that they applied for
- all applicants will be allotted a minimum of \$1,500 of new SPP Shares. Therefore, all applicants that have applied for \$1,500 in application monies will be allotted their full application
- if the scale back produces a fractional number, one extra SPP Share will be allocated.



The Company is of the view that the scaling methodology applied allows for the most equitable allocation taking into consideration shareholder holdings as at the Record Date.

Excess funds as a result of applying the scale back will be refunded to applicants without interest in accordance with the terms of the [SPP Booklet](#). To enable shareholders to receive their refund as quickly as possible by EFT, shareholders are strongly encouraged to update their bank details on the Automic Investor Portal at: <https://investor.automic.com.au/>. For refunds not processed by EFT, cheques will be mailed in the post to the relevant shareholders' registered address as shown in the share register. For any queries, shareholders should contact Automic at hello@automic.com.au.

Elixinol Global's Group CEO, Oliver Horn, said: *"We are delighted with the overwhelming interest we received from our shareholders wishing to participate in the SPP and thank them for their continued support. To exceed our SPP target is a very strong signal that our shareholders have the confidence in our business outlook especially now that the global regulatory environment has become more favourable. The SPP, along with the Placement, strengthens our balance sheet significantly during these uncertain COVID-19 times and will also allow us to pursue new growth opportunities whilst delivering on our strategy of becoming a global branded nutraceuticals business."*

It is expected that the New Shares will be issued on Friday, 18 December 2020, with quotation and the despatch of holdings statements expected to occur on or around Monday, 21 December 2020. The SPP Shares will rank equally with existing shares in the Company.

Unless otherwise defined, capitalised words in this announcement have the same meaning given to them in the [SPP Booklet](#).

This document was authorised to be given to the ASX by the Board of the Company.

For more information please contact:

Ron Dufficy
Chief Financial Officer
ron.dufficy@elixinolglobal.com

About Elixinol Global

Elixinol Global Limited (ASX:EXL; OTCQB:ELLXF) is a global leader in the hemp industry, innovating, marketing and selling hemp derived nutraceutical and food products. The Company's simplified business model is focusing on:

- In the Americas, innovating, marketing and selling high quality Elixinol branded hemp derived nutraceutical products based in Colorado, USA
- In Europe and the UK, educating and selling high quality Elixinol branded and co-branded hemp derived nutraceutical and skincare products based in Utrecht, The Netherlands and London, UK



- In Australia, providing stronger unified planning and support across the group to enable the various regional offices to focus on operational strategy and execution through its Global Executive Office based in Sydney, Australia
- Hemp Foods Australia Pty Ltd (Hemp Foods Australia), a leading hemp food wholesaler, retailer, manufacturer and exporter of bulk and raw materials, and finished products
- Across the Rest of World, expanding distribution of Elixinol branded hemp derived products through reputable distributors as key markets open.

See more at www.elixinolglobal.com